Takeda Pharmaceutical Company’s HilleVax HLVX Stock Holding History

Takeda Pharmaceutical Company’s Portfolio HLVX Stock Details HLVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-6,724,000	Closed	-$13.4M	–	9
2025 Q2	$13.4M	Hold	6,724,000	–	–	68.43%	1
2025 Q1	$9.75M	Hold	6,724,000	–	–	60.21%	1
2024 Q4	$13.9M	Hold	6,724,000	–	–	52.4%	1
2024 Q3	$11.8M	Hold	6,724,000	–	–	31.18%	1
2024 Q2	$97.2M	Hold	6,724,000	–	–	41.85%	2
2024 Q1	$112M	Hold	6,724,000	–	–	38.69%	1
2023 Q4	$108M	Buy	+6,724,000	New	+$89.3M	32.95%	1

Takeda Pharmaceutical Company's HLVX Position: Q3 2025 in Review

Takeda Pharmaceutical Company sold out of HilleVax (HLVX) in Q3 2025, closing a stake of 6,724,000 shares — an estimated $13.4M sold.

Takeda Pharmaceutical Company first reported a position in HLVX in Q4 2023 and held it in 7 quarters. The position peaked at $112M in Q1 2024. 1 fund tracked by Wall St. Rank holds HLVX as of Q3 2025.

Takeda Pharmaceutical Company reported no remaining HilleVax position as of Q3 2025 after selling out during the quarter.
Takeda Pharmaceutical Company sold 6,724,000 HilleVax shares in Q3 2025, an estimated $13.4M.
Takeda Pharmaceutical Company first reported a position in HilleVax in Q4 2023 and held it in 7 quarters.
Takeda Pharmaceutical Company's HilleVax position peaked at $112M in Q1 2024.
1 fund tracked by Wall St. Rank held HilleVax as of Q3 2025.

Based on Takeda Pharmaceutical Company's 13F filing for Q3 2025, filed 13 Nov 2025.